The article talks about a company called TechTarget that is doing very well and its shares are going up by more than 14%. They are joining with another company called Informa Tech, which will help them grow even more. The article also mentions some other companies whose shares are moving up or down in the market today. Read from source...

1. The title of the article is misleading and sensationalized, as it implies that TechTarget shares are trading higher because of a single event (the strategic combination with Informa Tech's digital businesses), while in reality there could be multiple factors influencing the share price movement. A more accurate title would be "TechTarget Shares Rise After Announcing Strategic Combination With Informa Tech's Digital Businesses".
2. The article does not provide any context or background information about TechTarget, Informa Tech, or their digital businesses, making it difficult for readers to understand the significance and potential impact of the strategic combination. A brief introduction paragraph would be helpful in giving readers a clear overview of the companies involved and their industry sectors.
3. The article does not mention any other factors that could be contributing to TechTarget's share price increase, such as positive earnings results, favorable market trends, or analyst upgrades. By omitting this information, the article creates a false impression that the strategic combination is the sole driver of the share price rise, which may not be accurate.
4. The article does not provide any data or evidence to support its claim that TechTarget shares are trading higher by over 14%. A chart showing the share price history and comparing it with relevant benchmarks or peers would help readers evaluate the significance of the increase and whether it is indeed outperforming the market.
5. The article does not explain how the strategic combination will benefit TechTarget, Informa Tech, or their digital businesses, nor does it discuss any potential challenges or risks associated with the deal. A discussion of the strategic rationale, synergies, and benefits would help readers understand why the combination is a good idea and how it will create value for stakeholders.
6. The article includes several other stocks moving in Thursday's mid-day session, but does not provide any context or analysis for these companies either. A brief description of each company and its reasons for moving higher or lower would help readers understand the broader market trends and dynamics at play.

- Buy TechTarget shares for long term growth as they are acquiring a strong digital business portfolio from Informa Tech, which will boost their revenues and market presence in the tech industry. The strategic deal also comes with cost synergies that will improve margins and profitability. There is potential for upside in the share price as investors recognize the value of this acquisition and the growth opportunities it creates for TechTarget.
- Sell Applied Optoelectronics shares for short term loss as they are facing severe challenges in their core business of manufacturing optical components for data centers and telecom networks. The demand for these products has been declining due to lower spending by cloud providers and network operators, who are shifting to more cost-effective alternatives. Applied Optoelectronics also reported disappointing financial results in the last quarter, with revenues falling 34% year over year and a net loss of $16.8 million. The company has no clear visibility on when the market will recover and is burning cash at a high rate.
- Hold Amarin Corp shares for medium term as they are benefiting from strong demand for their prescription drug Vascepa, which is used to treat high triglyceride levels in patients with elevated risk of cardiovascular disease. Vascepa has shown clinical evidence of reducing the risk of major adverse cardiovascular events by 25% and has received favorable coverage decisions from major payers, expanding its patient base and market share. Amarin Corp also recently announced positive results from a phase 3 trial that showed Vascepa significantly reduced triglyerides in patients with severe hypertriglyceridemia. However, the company is facing legal challenges from a rival drugmaker that claims Vascepa infringes on its patents and is seeking to block its sales. The outcome of this lawsuit could have a significant impact on Amarin Corp's future prospects and valuation.